Nick is a Chartered Engineer (MIMechE), technologist & has spent the last 10 years working in technology consultancies in the Cambridge cluster including nearly 5 years at Cambridge Consultants.
Prior to this Nick worked in industry in manufacturing engineering and mechanical design roles and was then a founder member of a spin-off company from a large FTSE100 technology firm (Smiths group) developing a novel medical diagnostic platform for veterinary and clinical diagnostics.
Nick has experience of developing devices in the broader medical technology area and has a particular focus on the development & commercialisation of platform technologies for biology & life sciences. His experience includes development of point of care diagnostics, instrumentation for synthetic biology (cell characterisation platform) & decentralised biomanufacturing solutions including manufacturing of Advanced Therapies.
Colin is a Biologist with an Engineering Habit. With a degree in Genetics and PhD in Toxicogenomics, he has a solid scientific background but over the years has broadened his skill set to include software programming, management and leadership and automation design and fabrication.
Colin has over a decade of experience in the development of commercial products and services from innovation and proof of concept through to commercialisation and ISO accreditation.
In addition to product development, Colin has worked at a strategic level, building new value propositions and refining business processes and workflows. With an emphasis on production methodologies and Design for Manufacture, this has enabled rapid scale-up, increased efficiency and reductions in Cost of Goods; allowing customers to be agile and disruptive in their relative markets and to better meet the needs of their customers.
Through his commitment to best practice in Leadership and Management, Colin holds a Fellowship of the Chartered Management Institute.
CFO of Horizon Discovery Group plc since 2012, leading one of the most successful ever Life Science IPOs on AIM raising £68.6m in a heavily oversubscribed IPO at the top of its valuation range, followed by two major US acquisitions within 6 months.
First class degree in Biological Sciences from Durham University and a qualified chartered accountant, advising numerous companies from lab bench to global pharma.
Previously Vice President, Finance at CSR plc, a FTSE 250 company with $1bn of revenues. Richard had worldwide responsibility for finance, with significant contributions to the $500m transformational acquisition and integration of NASDAQ listed Zoran Corp., product portfolio management, R&D financial management and business investment / divestment decisions.
Before this, Richard was a director in Deloitte’s life sciences practice, working with leading life science companies such as AstraZeneca, Vectura, Cambridge Antibody Technology and Abcam. He specialised in capital market transactions including numerous IPOs, M&As and fundraisings on AIM, Main Market and NASDAQ.
Beyond corporate responsibilities, Richard has advised the European Committee on funding for life science companies and is a regular presenter at investor conferences and technical seminars on financial issues facing the life science industry.